Malignant Neoplasm of Breast: Clinical Trials

8 trials for Malignant Neoplasm of Breast, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 active not recruiting, 2 unknown. 8 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 4, Active not recruiting 2, Unknown 2
Phase 11Active not recruiting 1

Follow Malignant Neoplasm of Breast: new trials by email Literature Review of Malignant Neoplasm of Breast trials Research Report on Malignant Neoplasm of Breast

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
Pembrolizumab Injection [Keytruda], Olaparib Oral Tablet [Lynparza] - Malignant Neoplasm of Breast, Breast Cancer
Phase 2Active not recruitingInstitut fuer Frauengesundheit112022-07-302024-05-07
Therapeutic Dose Monitoring (TDM) of Tamoxifen
Tamoxifen 20 mg - Breast Cancer, Breast Carcinoma
Phase 2UnknownKarolinska University Hospital402022-04-042022-05-25
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
Imprime PGG, Pembrolizumab - Malignant Neoplasm of Breast
Phase 2CompletedHiberCell, Inc.262021-11-092023-06-22
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
Pembrolizumab, nab-paclitaxel, Epirubicin - Malignant Neoplasm of Breast
Phase 2CompletedInstitut fuer Frauengesundheit532018-03-232021-04-08
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg - Breast Neoplasms, Malignant Neoplasm of Breast
Phase 1 / Phase 2Active not recruitingUS Oncology Research342017-11-292024-12-06
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Paclitaxel, Alisertib - Breast Cancer, Breast Carcinoma
Phase 2CompletedUS Oncology Research1692015-02-122024-10-09
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Genomically Directed Monotherapy, Observation/Standard Therapy - Malignant Neoplasm of Breast, Breast Cancer
Phase 2CompletedBryan Schneider, MD1932014-04-032023-09-28
ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes
ICG Fluorescence technique - Malignant Neoplasm of Breast
Phase 2UnknownPulsion Medical Systems SE1252011-09-012011-07-18

Narrower conditions

Breast Neoplasms (8)  ·  Triple Negative Breast Neoplasms (2)

Broader conditions

Breast Diseases (8)  ·  Neoplasms (8)  ·  Neoplasms by Site (8)  ·  Skin Diseases (8)  ·  Skin and Connective Tissue Diseases (8)

Interventions

pembrolizumab (3)  ·  Albumin-Bound Paclitaxel (2)  ·  Paclitaxel (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  BTH1677 (1)  ·  Cyclophosphamide (1)  ·  Epirubicin (1)  ·  Indocyanine Green (1)  ·  MLN 8237 (1)  ·  Observation (1)  ·  Standard of Care (1)  ·  Tamoxifen (1)  ·  Trastuzumab (1)  ·  ibrutinib (1)  ·  olaparib (1)

Sponsors

Institut fuer Frauengesundheit (2)  ·  US Oncology Research (2)  ·  Bryan Schneider, MD (1)  ·  HiberCell, Inc. (1)  ·  Karolinska University Hospital (1)  ·  Pulsion Medical Systems SE (1)

Countries

United States (4)  ·  Germany (3)  ·  Sweden (1)

Top investigators

Alison Stopeck, MD (1)  ·  Bryan Schneider, M.D. (1)  ·  Diethelm Wallwiener, Prof. Dr. (1)  ·  Elham Hedayati, MD PhD (1)  ·  Joyce A. O'Shaughnessy, MD (1)  ·  Joyce O'Shaughnessy, MD (1)  ·  Peter A Fasching, MD, Prof. (1)  ·  Peter A. Fasching, MD, Prof. (1)

Results publications

PMID 32644110, PMID 33877311, PMID 34910554, PMID 38745646, PMID 42504645

NIH funding

2016 (1)